Yossi Febriani

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

Danuta M. Skowronski, Yossi Febriani, Solmaz Setayeshgar et al. · Clinical Infectious Diseases · 2022 · 135 citations · Full text

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

Danuta M. Skowronski, Solmaz Setayeshgar, Yossi Febriani et al. · 2021 · 60 citations · Full text

Vaccination, Vaccine Safety, Age Group +11

Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada

Sara Carazo, Danuta M. Skowronski, Marc Brisson et al. · The Lancet Healthy Longevity · 2023 · 23 citations · Full text

Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk

Nicholas Brousseau, Sara Carazo, Yossi Febriani et al. · Clinical Infectious Diseases · 2023 · 19 citations · Full text

Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study

Sharifa Nasreen, Yossi Febriani, Héctor Alexander Velásquez García et al. · Clinical Infectious Diseases · 2022 · 18 citations · Full text